XPA Peptide
€100.00
In stock
SKU
350530
Protein Family: Enzymes
Pathway and Disease: Cancers, Replication and Repair
Alternate Names: DNA-repair protein complementing XP-A cells; Xeroderma pigmentosum group A-complementing protein; XPA; XPAC
Accession No.: P23025, NP_000371
Description:
Xeroderma pigmentosum group A-complementing protein (XPA) is involved in DNA excision repair by binding to damaged sites with various affinities depending on photoadduct and transcriptional state. Defects in XPA are a cause of xeroderma pigmentosum complementation group A characterized by solar sensitivity and skin cancer predisposition.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 2229.3 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200168 is selected from a sequence within the C-term region of human XPA. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C93H137N25O35S2
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Replication and Repair
Alternate Names: DNA-repair protein complementing XP-A cells; Xeroderma pigmentosum group A-complementing protein; XPA; XPAC
Accession No.: P23025, NP_000371
Description:
Xeroderma pigmentosum group A-complementing protein (XPA) is involved in DNA excision repair by binding to damaged sites with various affinities depending on photoadduct and transcriptional state. Defects in XPA are a cause of xeroderma pigmentosum complementation group A characterized by solar sensitivity and skin cancer predisposition.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 2229.3 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200168 is selected from a sequence within the C-term region of human XPA. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C93H137N25O35S2
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review